Upload Image (Max 20MB per Image)
MagForce has obtained German Federal Institute for Drugs and Medical Devices' (BfArM) approval for the start of a post-marketing clinical study in recurrent glioblastoma patients. The controlled, open-label and randomized study will ...
Tags: Magforce, Post-Marketing Study, Nanotherm Therapy